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Abstract
Mitochondrial dysfunction connects metabolic disturbance with numerous pathologies, but the significance of mitochondrial
activity in bone remains unclear. We have, therefore, characterized the skeletal phenotype in the Opa3L122P mouse model for
Costeff syndrome, in which a missense mutation of the mitochondrial membrane protein, Opa3, impairs mitochondrial
activity resulting in visual and metabolic dysfunction. Although widely expressed in the developing normal mouse head,
Opa3 expression was restricted after E14.5 to the retina, brain, teeth and mandibular bone. Opa3 was also expressed in adult
tibiae, including at the trabecular surfaces and in cortical osteocytes, epiphyseal chondrocytes, marrow adipocytes and
mesenchymal stem cell rosettes. Opa3L122P mice displayed craniofacial abnormalities, including undergrowth of the lower
mandible, accompanied in some individuals by cranial asymmetry and incisor malocclusion. Opa3L122P mice showed an 8-
fold elevation in tibial marrow adiposity, due largely to increased adipogenesis. In addition, femoral length and cortical
diameter and wall thickness were reduced, the weakening of the calcified tissue and the geometric component of strength
reducing overall cortical strength in Opa3L122P mice by 65%. In lumbar vertebrae reduced vertebral body area and wall
thickness were accompanied by a proportionate reduction in marrow adiposity. Although the total biomechanical strength of
lumbar vertebrae was reduced by 35%, the strength of the calcified tissue (rmax) was proportionate to a 38% increase in
trabecular number. Thus, mitochondrial function is important for the development and maintenance of skeletal integrity,
impaired bone growth and strength, particularly in limb bones, representing a significant new feature of the Costeff
syndrome phenotype.
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Introduction
The mitochondrion represents a sub-cellular powerstation, uti-
lizing protons from dietary carbohydrates and fat to generate
heat and adenosine triphosphate. This function is particularly
vital in tissues with high energy demands, such as the central
nervous system, muscle, brown adipose tissue (BAT) and the
endocrine glands. As a consequence, defective mitochondrial
function is emerging as a potentially important mechanistic
link between metabolic disturbance and the development of a
wide range of pathologies (1,2,3).
A number of lines of evidence suggest that mitochondrial
function may also be important in bone growth and mineraliza-
tion. For example, in the context of longitudinal growth, chon-
drocyte maturation in the epiphyseal plate is accompanied by
increased mitochondrial number and decreased mitochondrial
size (4). Once in the hypertrophic zone, the chondrocyte mito-
chondria regulate calcification (5), a decrease in mitochondrial
membrane potential accompanying subsequent chondrocyte
apoptosis (6,7). In the context of bone remodelling, mitochon-
dria are also abundant in both osteoblasts (8) and osteoclasts
(9). In the osteoblastic lineage increased mitochondrial activity
regulates osteoblast differentiation (10,11), the subsequent de-
velopment of mitochondrial granules in fetal bone representing
the first mineral deposits in the osteoid (12,13). Indeed, increas-
ing mitochondrial calcium uptake in osteoblasts is thought to
mediate the parathyroid hormone (PTH)-induced reduction in
mitochondrial membrane potential (14). In addition, the expres-
sion of genes associated with mitochondrial dysfunction are
rapidly increased following mechanical loading (15), with ex-
treme mechanical loading of osteoblastic cells inhibiting mito-
chondrial activity and enhancing reactive oxygen species
production (16). Although mitochondrial biogenesis is co-
ordinated with osteoclast development (17), little is known
about the functional role of osteoclast mitochondria. Despite
these strands of evidence, the overall effect of mitochondrial
dysfunction on bone integrity remains poorly characterized.
To address this question, we have characterized the bone phe-
notype in a murine model of primary mitochondrial dysfunction,
the B6; C3-Opa3L122P mouse (hereafter referred to as the Opa3L122P
mouse; (18). The Optic atrophy 3 (OPA3) gene gives rise to the pro-
duction of Opa3A (hereafter called Opa3), a 179 amino acid peptide
containing an N-terminal mitochondrial targeting sequence (19,20),
which directs expression to either the inner (21) or outer (20,22) mi-
tochondrial membrane where it induces mitochondrial fragmenta-
tion (20). Mutations in Opa3A lead to the development of the
hereditary optic neuropathy known as type III methylglutaconic
aciduria (3-MGA) or Costeff syndrome (MIM 258501) (19,23).
Homozygous Opa3L122P mice display the characteristic Costeff
phenotype of 3-MGA (24), reduced visual acuity, spasticity and
extrapyramidal dysfunction (18). However, we have recently
shown that disrupted mitochondrial morphology in Opa3L122P
mice (25) is accompanied by phenotypic abnormalities not previ-
ously reported in the human Costeff syndrome kindreds,
impaired thermogenesis in the BAT resulting in profound intra-
abdominal leanness and post-natal growth retardation (24).
In this study, we have characterized Opa3 mRNA expression
in the murine skeleton and examined the effect of the Opa3L122P
mutation on skeletal integrity, including the 3-dimensional (3D)
morphology of the skull, tibial and vertebral marrow adiposity
and the geometry, trabecular microarchitecture and mechanical
strength of the femora and lumbar vertebrae. This study dem-
onstrates the impact of mitochondrial dysfunction on skeletal
integrity, uncovering a striking novel aspect of the Costeff syn-
drome phenotype.
Results
Skeletal Opa3 expression
Opa3 was expressed ubiquitously in the developing head of WT
mice until E13.5 (Fig. 1A and B), but from E14.5 expression of
Opa3 became more restricted, being seen in the developing sub-
mandibular salivary glands at E14.5 (Fig. 1Ci), the sensory layer
of the retina and in hair follicles (Fig. 1Cvii and Di) and the de-
veloping brain and mandibular bone, but not in Meckel’s carti-
lages (Fig. 1Cii and iii), or in developing skull bone (Fig. 1Dii).
Expression was also observed in developing cap stage tooth
germs at E14.5 (Fig. 1Civ–vi), whilst in the molars, Opa3 was
strongly expressed in odontoblasts while it was weakly ex-
pressed in ameloblasts at E18.5 (Fig. 1Diii). In the incisors the
immature odontoblasts showed strong Opa3 expression
whereas Opa3 was weakly expressed in mature odontoblasts at
E18.5 (Fig. 1Div–vii). In contrast, strong Opa3 expression was ob-
served in ameloblasts in both anterior and posterior regions of
incisors at E18.5 (Fig. 1Div–vii).
Immunohistochemistry (IHC) was used to show that the most
pronounced Opa3 expression in adult tibiae was observed in the
marrow cavity (Fig. 2A). Discrete expression was observed in cells
on the endosteal and trabecular surfaces (Fig. 2C) and on the sur-
faces of the cortical periosteum (Fig. 2E) and synovial cartilage
(Fig. 2G). In addition, Opa 3 immunoreactivity was seen in cortical
osteocytes (Fig. 2E) articular chondrocytes (Fig. 2G) and in the ger-
minal, proliferative and hypertrophic chondrocytes of the proxi-
mal epiphyseal plate (Fig 2I and K). In the marrow cavity, Opa
3 immunoreactivity was observed around the unilocular lipid
droplets of the adipocytes (Fig. 2I and K) and in distinct rosettes
of mesenchymal stem cells in the mid-diaphyseal marrow
(Fig. 2M).
Skull bone structure in Costeff syndrome mice
No abnormalities were observed in heads of E18.5 Opa3L122P
mice (data not shown), but micro-computed tomography (m-CT)
analysis revealed an impairment in postnatal skull develop-
ment. Overall skull length was reduced by 10% in Costeff syn-
drome mice at P14 (Table 1, Fig. 3; P< 0.001), which appears to
be accompanied in adult mice by a shortening of the snout
(Fig. 3). An 8% reduction in nasal height in Costeff syndrome
mice at P14 (Table 1 and Fig. 3; P< 0.05) was accompanied by re-
ductions of 11% and 14% in the height and length of the lower
mandible (Table 1 and Fig. 3; P< 0.01 and P< 0.001 respectively).
Individual Costeff syndrome mice displayed varying degrees of
cranial asymmetry, which was particularly observable in the
shape of the occipital bone and accompanied by misalignment
of the lower mandible and incisors (Table 1 and Fig. 3; P< 0.05).
At P14 mean incisor length in Costeff syndrome mice was 86%
of that in WT littermates, but this was only significantly differ-
ent in the lower incisors (Table 1 and Fig. 3; P< 0.05). However,
malocclusion in adult Opa3L122P mice (Fig. 3) was accompanied
in some individuals by incisor elongation.
Marrow adiposity in Costeff syndromemice
Adiposity in the tibial marrow cavity of Opa3L122P mice was in-
creased 8-fold (Fig. 4A; P< 0.05), due largely to a 6-fold elevation
2405Human Molecular Genetics, 2016, Vol. 25, No. 12 |
Downloaded from https://academic.oup.com/hmg/article-abstract/25/12/2404/2525732
by University of Bristol Library user
on 17 May 2018
in adipocyte number (P< 0.05). This increase was especially
prominent at the lower end of the size spectrum (Fig. 4A), with
mean size being unaffected (inset). In contrast, although overall
marrow adiposity in the L3 vertebral body was unaffected (Fig.
4B), the total number of marrow adipocytes was reduced in
Opa3L122P mice by 45% (P< 0.05). This reduction was especially
prominent for smaller adipocytes, with mean size unaffected
(Fig. 4B inset). It should be noted that since the cross sectional
area of the vertebral marrow compartment in Opa3L122P mice
was only 79% of that in WT mice (P¼ 0.055), this reduction in ad-
ipocyte number was proportionate to the size of the vertebral
marrow compartment (data not shown).
Femoral structure and strength in Costeff syndrome
mice
Opa3L122P mice showed a 25% reduction in femoral length (Fig.
5A; P< 0.001), with outer cortical diameter at the site of strength
testing reduced in Opa3L122P mice by 13% (Fig. 5A; P< 0.05).
Although mean inner diameter in Costeff syndrome mice was
only 90% of that in WT mice, this was not statistically signifi-
cant (P¼ 0.072), but mean wall thickness in the mid-diaphyseal
cortex was reduced by 31% (Fig. 5A; P< 0.01).
A 33% reduction in trabecular volume of Costeff syndrome
mice (bone volume (BV); Fig. 5B; P< 0.01), was in direct propor-
tion to the 35% reduction in total volume (TV; P< 0.01; data not
shown), so that relative trabecular volume (BV/TV; Fig. 5B) and
relative trabecular surface (BS/BV; Fig. 5B) were unaffected.
Trabecular number (Tb.N) was elevated in the Opa3L122P mice by
13% (Tb.N; Fig. 5B; P< 0.05), and with no change in trabecular
thickness (Tb.Th; Fig. 5B), trabecular separation (Tb.Sp) was re-
duced by 19% (Tb.Sp; data not shown; P< 0.05).
Three-point bending revealed that mechanical strength of the
mid-diaphyseal cortex (Ultimate moment) was profoundly com-
promised in Costeff syndrome mice, being reduced by 65%
(Fig. 5C; P< 0.001). This was due to a combination of a 35%
reduction on the strength of the calcified tissue per se (ultimate
tensile stress; Fig. 5C; P< 0.01) and a 55% reduction in the geomet-
ric contribution (second moment of area; Fig. 5C; P< 0.01).
Given the clear association between femoral strength and
Figure 1. Opa3 mRNA expression in the developing mouse head. Radioactive in situ hybridisation of Opa3 mRNA expression in E10.5 (A) E11.5 (B) E14.5 (C) and E18.5
(D) heads of male WT mice. Expression was seen in the submandibular salivary glands (arrow in Ci), developing mandibular bone surrounding Meckel’s cartilage
(short arrows in Cii and iii), lower incisor (arrow in Civ), upper molar (arrow in Cv), lower molar (short arrow in Cv), upper incisors (arrow in Cvi), sensory layer of ret-
ina (short arrow in Cvii) at E14.5, the hair follicles (arrows in Di), brain (short arrow in Dii) skull bone (arrow in Dii) and upper molar tooth germ (arrow in Diii)
at E18.5 and the ameloblasts (short arrows in Div–vii) and odontoblasts (arrows in Div–vii) of anterior incisors (Div and vi) and posterior part of incisors (Dv and vii)
at E18.5.
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Figure 2. Immunolocalisation of Opa3 in mouse tibiae. Immunohistochemical visualisation of Opa3 expression in 6-month-old WT tibiae with (A,C,E,G,I,K,M,O) and
without (B,D,F,H,J,L,N) application of the primary rabbit anti-mouse Opa3 antibody, using the ImmPRESS peroxidase secondary antibody in conjunction with BCIP/NBT
(5-bromo-4-chloro-3-indolyl phosphate/nitroblue terazolium) peroxidase substrate to produce indigo labelling, all sections being counterstained with haematoxylin
and eosin. The immunoreactivity observed under low power (A) was located in osteoblasts on the endosteal (black arrowheads) and trabecular (grey arrowheads) (C),
surfaces and on the surface of the cortical periostium (white arrowheads; E) and synovial cartilage (light grey arrowheads; G). In addition, Opa3 immunoreactivity was
observed in cortical osteocytes (black arrows; E), synovial chondrocytes (dark grey arrows; G), germinal (g), proliferative (p) and hypertrophic (h) growth plate chondro-
cytes (I,K), mesenchymal stem cell rosettes (white arrows) in the mid-diaphyseal marrow (M) and adipocytes in the proximal (*; I,K) and distal (v;O) marrow (Scale bars:
300 mm (A,B), 50mm (C,D,I,J,M,N,O) and 20 mm (E,F,G,H,K,L).
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body weight (Fig. 5C; R2¼0.9118), body weight-corrected femoral
strength was not significantly different in the Opa3L122P model for
Costeff syndrome.
Vertebral structure and strength in Costeff syndrome
mice
As in our microscopic quantification of the marrow compart-
ment in the L3 vertebral body above, the size of the L5 vertebrae
in Opa3L122P mice was reduced in all dimensions, vertebral
length, and the cross sectional area of the vertebral body being
reduced by 24% (Fig. 6A; P< 0.001) and 15% (Fig. 6A; P< 0.05) re-
spectively. The thickness of the cortical bone surrounding the
vertebral body was also reduced by 28% (Fig. 6A; P< 0.001).
As in the femora, trabecular structure in the L5 vertebrae
was characterized by a denser lattice of smaller trabeculae. This
was due to a 38% increase in Tb.N (structure linear density; Fig.
6B; P< 0.01), a 9% increase in relative surface (BS/BV; P< 0.01),
with Tb.Th and Tb.Sp reduced by 5% (Tb.Th; Fig. 6B; P< 0.05)
and 25% (Tb.Sp; Fig. 6B; P< 0.01) respectively. The relative pre-
ponderance of rod- or plate-like trabeculae (structure modal in-
dex), and the connectivity (pattern factor) and orientation of the
trabecular lattice (degree of anisotropy) were not significantly
affected in Costeff syndrome mice (data not shown).
Despite this evidence of a denser trabecular lattice in Costeff
syndrome vertebrae, the load required to crush the L5 vertebral
body of Opa3L122P mice (maximum load required, Fmax) was re-
duced by 35% (Fig. 6C; P< 0.05). Interestingly, given the relation-
ship between Fmax and cross sectional area (Fig. 6C), calculation
of maximum stress (rmax) revealed that mean rmax in Costeff
syndrome mice was 169% of that in WT mice, though this was
Table 1. Skull morphometry in 14-day-old WT and Opa3L122P
littermates
WT (n¼9) Opa3L122P(n¼5)
Skull Length (mm) 17.43 6 0.21 15.76 6 0.29 ***
External cranial volume (mm3) 1892.37 6 93.82 1644.25 6104.83
Cranial dome angle () 25.1 6 1.5 23.9 6 1.9
Nasal height (mm) 3.88 6 0.06 3.56 6 0.12 *
Nasal length (mm) 4.69 6 0.14 4.54 6 0.25
Mandibular height (mm) 3.38 6 0.08 3.00 6 0.06 **
Mandibular length (mm) 6.06 6 0.09 5.23 6 0.11 ***
Upper incisor length (mm) 1.67 6 0.10 1.45 6 0.04
Lower incisor length (mm) 2.36 6 0.08 2.04 6 0.09 *
Incisor misalignment (mm) 0.03 6 0.01 0.16 6 0.06 *
Values shown are mean6SEM (n¼9 (WT; 4 males/5 females) and 5 (Opa3L122P;
3 males/2 females)), with statistical comparisons performed with unpaired
Student’s t-test.
*P<0.05.
**P< 0.01.
***P<0.001.
Dorsal FrontalLateral
WT
(14 days old)
Opa3L122P
(14 days old)
WT
(4 months old)
Opa3L122P
(4 months old)
Figure 3. Opa3L122P mice show abnormal skull formation. 3D reconstructions of m-CT scans showing dorsal, lateral and frontal aspects of juvenile (14-day old) and adult
(4-month old) male WT and Opa3L122P littermate mouse skulls (scale bar 2 mm).
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not statistically significant (P¼ 0.065). Given the weak relation-
ship between rmax and Tb.N (data not shown), normalization of
rmax to Tb.N, revealed that any elevation in maximum stress in
Costeff syndrome vertebrae was entirely due to the denser tra-
becular lattice (Fig. 6C).
Discussion
Costeff syndrome is a mitochondriopathy in which mutations
in the mitochondrial membrane protein, Opa3, result in a range
in neurological deficits. Mice bearing a missense mutation of
Opa3 recapitulate many of the symptoms of this condition
(18,24,25) and exhibit a metabolic impairment not previously as-
sociated with Costeff syndrome (24). Given the bi-directional re-
lationship between fat and bone (26), we characterized the
skeletal phenotype in this model for Costeff syndrome, shed-
ding new light on the role of mitochondria in bone physiology
and of the impact of this condition on skeletal integrity.
Our data reveal Opa3 to be expressed in both the developing
and adult mouse skeleton and that global mitochondrial dys-
function in Costeff syndrome mice has marked consequences
for skeletal growth and homeostasis. In the hindlimb, elevated
marrow adiposity is accompanied by reductions in femoral size
and tissue strength, resulting in profoundly compromised corti-
cal strength. In contrast, although the compressive strength of
the vertebrae is reduced, the trabecular contribution to strength
is increased in parallel with the rise in Tb.N, marrow adiposity
being slightly reduced. Although we did not analyse the biome-
chanical properties of the skull, skulls of Costeff syndrome mice
showed evidence of reduced longitudinal growth. This was
most prominent in the lower mandible in which Opa3 was
prominently expressed during embryogenesis.
Several mechanisms may account for these changes. Firstly,
the reduction in ultimate tensile stress in the femoral cortex
implies that the processes of matrix formation and/or minerali-
zation are compromised. The reduced cortical thickness in both
femora and vertebrae, when combined with our evidence for
Opa3 expression in discrete cells on the endosteal surface sug-
gests impairment of osteoblast function. Indeed, previous re-
ports that osteoblast mitochondria regulate differentiation
(10,11) and mineralization (12,13,14) support this proposal.
However, the increased Tb.N in Costeff syndrome mice in-
dicates that mitochondria may play a different role in cancel-
lous bone. Increased trabecular density could result from
either elevated osteoblastic activity, or reduced osteoclastic
activity. Our evidence seems to favour the former, as Opa3 im-
munoreactivity is most pronounced on the convex surfaces of
the trabeculae, which suggests osteoblast-specific expression.
The increased trabecular density not only accounts for the po-
tential increase in rmax in Costeff syndrome vertebrae, but ex-
plains why the deficit in mechanical strength of the vertebrae,
in which trabecular structure makes a greater contribution, is
less pronounced than in the femoral cortex. Indeed, since in
compression testing the trabeculae fail as a result of buckling,
their strength may be enhanced as a result of a reduction in
their unsupported length.
Whilst it may be possible that osteoblast mitochondria exert
differential effects in these two types of bone, an alternative ex-
planation is that the weakening of cortical bone in Costeff syn-
drome mice results from a failure in the maintenance of
B  Vertebral marrow adiposity
WT Opa3L122P
A  Tibial marrow adiposity
Marrow adiposity
a
Adipocyte number
a
Mean size
Adipocyte Size
a
a
a
aa
a
Size distribution
Marrow adiposity
W-T
Opa3L122P
W-T
Opa3L122P
Adipocyte number
a
Mean size
Adipocyte Size
Size distribution
a
a
Figure 4. Opa3L122P mice show site-specific dysregulation of marrow adiposity. Digital analysis of photomicrographs (inset; (adipocytes: black arrows); scale bar 20 mm
(tibial images) 50 mm (vertebral images)) to quantify marrow adiposity, adipocyte number, adipocyte size and size distribution in tibiae (A) and L3 vertebrae (B) from 30-
day-old male WT (n¼6 (tibiae) and 5 (vertebrae)) and homozygous Opa3L122P littermate mice (n¼6 (tibiae) and 3 (vertebrae)). Data presented are mean6SEM, with sta-
tistical analysis performed by unpaired Student’s t test; a P<0.05 versus WT males.
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skeletal integrity. This is supported by our demonstration of
marked Opa3 expression in cortical osteocytes.
In addition to these direct effects on bone cell activity, the
relationship between cortical strength and body weight implies
a contribution from the more indirect consequences of mito-
chondrial impairment. In this context, the positive relationship
between mechanical load and bone strength (27) may be signifi-
cant. Loss of mitochondrial function in BAT of Costeff syndrome
mice results in profound intra-abdominal leanness and a 60%
reduction in body weight (24). This partial unloading may ex-
plain the greater impairment in the load-bearing limb bones
than in the axial bones. Although the relatively normal appear-
ance of the calvarial bone supports this hypothesis, several ad-
ditional factors may also contribute to this phenotype.
Given their degree of leanness, Costeff syndrome mice are
likely to be hypoleptinemic. While hyperleptinemia is thought to
B  Trabecular architecture
Trabecular volume
aa
Relative volume Relative surface Trabecular number
a
Trabecular thickness
Body weight-strength   
relationship
WT
Opa3L122P
C  Cortical strength
Organ strength
aaa
Tissue strength
aa
Geometric contribution
aa
Weight-corrected strength
A  Femoral geometry
Femoral length
aaa
Cortical diameter (outer)
a
Cortical diameter (inner) Cortical wall thickness
aa
Figure 5. Opa3L122P mice show compromised femoral strength. Geometry (A) trabecular architecture (B) and mechanical strength of the cortex (C) were quantified in
femora from 30-day-old male WT (n¼5) and homozygous Opa3L122P littermate mice (n¼5). Data presented are mean6SEM, with statistical analysis performed by un-
paired Student’s t test; a P<0.05; aa P<0.01, aaa P<0.001 versus WT males.
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suppress bone formation via a central mechanism (28,29), lep-
tin within the normal range directly promotes osteoblastic activ-
ity (30,31). Thus, loss of circulating leptin may contribute to the
compromised bone integrity. However, the marked truncal lean-
ness is accompanied by a remarkable rise in tibial marrow adipo-
genesis. Since marrow adipocytes themselves produce high levels
of leptin (32) and direct infusion of leptin into the tibial marrow
cavity increases osteoblast surface and reduces marrow adipogene-
sis (33), the presence of weakened limb bones in the context of a
sustained increase in marrow adiposity in Costeff syndrome mice
implies that this action of leptin is dependent upon mitochondrial
activity. Indeed, the importance of mitochondrial activity is empha-
sized by the combination of increased marrow adiposity and Tb.N
in the limb bones of Opa3L122P mice. The parallel increase in these
parameters is unusual, as Tb.N is normally inversely related to
marrow adiposity (34), especially in the context of dietary manipu-
lation (35).
The site-specific changes in marrow adiposity deserve com-
ment. Like intra-abdominal adipocytes, tibial marrow adipo-
cytes are exquisitely sensitive to growth hormone (GH), ghrelin
and leptin exposure, but are unresponsive to insulin-like
growth factor-1 (IGF-1) and PTH (34,36,37). However, given the
profound leanness in Costeff syndrome mice (24), the current
study reveals that marrow adipocytes are not only regulated in-
dependently of intra-abdominal adipocytes, but are even regu-
lated differentially in the two locations studied. Although the
physiological significance of marrow fat is not fully understood,
periods of caloric restriction have been reported to elevate mar-
row adiposity (38), while marrow adiposity is conserved during
starvation (39) and in patients with acquired generalized lipo-
dystrophy (40). This situation may reflect the sensitivity of these
cells to ghrelin, which promotes adipogenesis rather than lipid
storage in marrow adipocytes (33), thereby defending this fat
deposit against utilisation (41).
Cortical bone thickness
aaa
Vertebral body area
a
A  Vertebral geometry
Vertebral length
aaa
B  Trabecular architecture
Trabecular volume
WT
Opa3L122P
C  Mechanical strength
Relative surface
aa
Trabecular thickness
a
Trabecular number
aa
Tb
.N
 
(m
m-
1 )
Trabecular separation
aa
Maximum stressMaximum load
a
Cross sectional area-
strength relationship
R2 = 0.6291
Normalized maximum 
stress
Figure 6. Opa3L122P mice show compromised vertebral strength. Geometry (A) trabecular architecture (B) and mechanical strength (C) were quantified in L5 lumbar ver-
tebrae from 30-day-old male WT (n¼5) and homozygous Opa3L122P littermate mice (n¼5). Data presented are mean6SEM, with statistical analysis performed by un-
paired Student’s t test; a P<0.05; aa P<0.01, aaa P<0.001 versus WT males.
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These considerations aside, the profile of fat distribution
seen here in Costeff syndrome mice is unusual, even in the con-
text of murine lipodystrophy (42). Therefore comparison with
rodent models showing a similar distribution may suggest addi-
tional potential mechanisms. For example, several of the phe-
notypic characteristics of Costeff syndrome mice seen here are
replicated in the profoundly GH-deficient dwarf (dw/dw) rat.
These animals, bearing an unknown mutation, display truncal
leanness and hypoleptinemia (43), with elevated marrow adi-
posity and compromised femoral strength (44). Indeed, other ro-
dent models of GH-deficiency/insensitivity also show reduced
mandibular growth and malocclusion (45,46). Direct measure-
ment of episodic GH secretion in Costeff syndrome mice would
be technically challenging, but the dramatic reduction in circu-
lating IGF-1 (24) indicates that further analysis of mitochondrial
function in the GH-IGF-1 axis of Costeff syndrome mice is now
required.
Our study highlights the potential subcellular role of Opa3 in
adipocytes and bone mitochondria. A recent report indicates
that Opa3 binds to the molecular chaperone, prohibitin (47),
which maintains the integrity of the inner mitochondrial mem-
brane (48) and shuttles cardiolipin between the mitochondria
and the nucleus (49). Thus, failure of Opa3 to anchor prohibitin
to the inner mitochondrial membrane of Costeff syndrome
mice would render tissues with high energy demands suscepti-
ble to hypoxia and oxidative stress. Our data indicate that this
function may be important in the cells regulating bone develop-
ment and health.
When taken together, we have demonstrated that homozy-
gous Opa3L122P mice display the hallmark characteristics of
Costeff syndrome, 3-MGA (24), retinal abnormality, optic atro-
phy and loss of visual acuity consistent with optic nerve degen-
eration (18). Other neural deficits include spasticity and
extrapyramidal dysfunction and gross neuromuscular defects
(18). In addition, the disrupted mitochondrial morphology in
Opa3L122P mice (25) results in reduced lifespan, dilated cardio-
myopathy (18) and impaired thermogenesis in interscapular
BAT resulting in profound intra-abdominal leanness (24). We
have now shown that these metabolic disturbances are accom-
panied by post-natal growth retardation (24), compromised
skeletal development and impaired biomechanical integrity.
Undergrowth of the lower mandible in Opa3L122P mice is accom-
panied in some individuals by cranial asymmetry and incisor
malocclusion. Reduced tibial length (24) is accompanied by a
marked elevation in tibial marrow adiposity. Reductions in fem-
oral length, cortical diameter and wall thickness, together with
weakening of the calcified tissue, result in a markedly compro-
mised cortical strength. Although vertebral body area and wall
thickness were reduced in lumbar vertebrae and the total bio-
mechanical strength was reduced, the strength of the calcified
tissue was increased in proportion to the elevated Tb.N. Despite
these multi-system abnormalities in homozygous Opa3L122P
mice heterozygous mice, at least in relation to their general ap-
pearance and the optic and neural defects, are indistinguishable
from their WT littermate controls (18).
In summary, the current study demonstrates that impaired
mitochondrial function in the Opa3L122P model for Costeff syn-
drome disturbs the functional relationship between adipocytes,
osteoblasts and osteoclasts, resulting in compromised mechan-
ical performance of both axial and limb bones. Given that the
processes of longitudinal bone growth and skeletal remodelling
are remarkably similar in rodents and humans (50), our data
have significant implications for individuals with Costeff syn-
drome. Although evidence has recently emerged of limb
dystonia (51,52) and ataxia (52,53), there do not appear to be any
extant studies of skeletal development, bone microarchitecture
or fracture risk in the identified Costeff syndrome kindreds.
Although it is possible that the skeletal impairment in the
Opa3L122P mice relates to the specific mutation in this model,
Costeff syndrome has been reported in humans with mutations
in exon2 of Opa3 (19,23). In the light of our current study, an in-
vestigation of bone health in individuals with this condition
should now be undertaken. Indeed, when taken together with
recent evidence indicating that low circulating mitochondrial
DNA is associated with decreased femoral neck bone mineral
density in postmenopausal women (54), our study indicates
that a wider analysis of the importance of mitochondrial activ-
ity to bone health is now necessary.
Materials and Methods
Animals
The procedures described conformed to the institutional and
national ethical guidelines for animal experimentation, includ-
ing those for genetically modified animals, and were specifically
approved by local ethical review. Mice were bred in the JBIOS fa-
cility at Cardiff University and housed under conditions of 12 h
light:12 h dark (lights on at 06.00 h), ambient temperature (19–23
C), with food (Harlan Teklad Rodent Maintenance Diet contain-
ing 4.9% oil and 14.2% protein) and water available ad libitum.
To investigate Opa3 mRNA expression in WT mouse head
development, heads were collected from CD1 mice at E10.5,
E11.5, E14.5 and E18.5, fixed in 4% paraformaldehyde and
decalcified in 0.5 M EDTA (pH 7.6), paraffin-embedded and seri-
ally sectioned at 7 mm, with sections distributed between 5–10
slides. Radioactive in situ hybridization (ISH) using 35S-UTP
radiolabelled riboprobes was carried out as described previ-
ously (55). Tibiae were collected from 6-month-old male WT
mice (C57Bl6) killed by cervical dislocation for subsequent
identification of Opa3 distribution by IHC.
To investigate the effect of the L122P mutation on cranial de-
velopment, an additional cohort of whole heads were collected
from WT and Opa3L122P mice at E18.5. Heads were fixed in 95%
ethanol, stained with Alcian blue and Alizarin red S, cleared by
KOH treatment and stored in 100% glycerol prior to whole
mount visualization under light microscopy. Additional whole
heads were collected from young (P14) and adult (4-month old)
WT and Opa3L122P littermates were killed by either anaesthesia
with isoflurane and decapitation, or lethal injection and stored
in 4% paraformaldehyde prior to analysis of the structure of the
skull, jaw and denture by m-CT.
The remaining studies were performed on tissue collected
from male homozygous Opa3L122P mice and WT littermates
killed by decapitation at 30 days of age after being anaesthe-
tized with isofluorane. Right tibiae and femora were excised
and cleaned of soft tissue. Tibiae were fixed and decalcified
prior to paraffin-embedding and quantification of marrow adi-
posity. Femora were wrapped in saline soaked gauze and
stored at 70C prior to quantification of trabecular architec-
ture and strength testing. In addition, the spine was exposed
and vertebrae L2–L6 excised. L3 and L5 vertebrae were care-
fully dissected and cleaned of soft tissue. L3 vertebrae were
fixed overnight in buffered formal saline and decalcified for 2
weeks prior to quantification of marrow adiposity. L5 vertebrae
were wrapped in saline-soaked gauze and stored at 70C
prior to quantification of trabecular architecture and mechani-
cal strength.
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Immunohistochemistry for Opa3
An IHC approach was developed for visualisation of Opa3 distri-
bution in 7 mm sections of paraffin-embedded tissue from WT
mice. A rabbit anti-human/mouse/rat Opa3 primary antibody
(optimal dilution 1:100; Cat # 15638-1-AP; ProteinTech, Chicago,
IL, USA) in combination with the ImmPRESS peroxidase second-
ary antibody and the BCIP/NBT (5-bromo-4-chloro-3-indolyl
phosphate/nitroblue terazolium) peroxidase substrate (Cat #s
MP-7401 & SK-5400; Vector Laboratories Inc., Burlingame, CA,
USA) was used to visualise Opa3 expression, the tissue being
counterstained with haematoxylin and eosin. The method was
initially developed for use with BAT, which showed marked ex-
pression surrounding the lipid-containing vesicles, and subse-
quently applied to tibial sections. No Opa3 immunoreactivity
was seen on omission of the primary antibody (Fig. 2).
Microstructural analysis with m-CT
Heads
Heads of WT and Opa3L122P mice were scanned with an Explore
Locus SP (GE Pre-Clinical Imaging, London, Canada). The heads
were immobilised using cotton gauze and scanned to produce
28 mm voxel size volumes, using an X-ray tube voltage of 80 kVp
and a tube current of 80 mA. An aluminium filter (0.05 mm) was
used to adjust the energy distribution of the X-ray source. The
heads were characterised by making 3D slice volumes and seg-
mented using automatic threshold functioning. Stacked 2-D
scans were rendered into 3D using ImageJ (1.49v for MacIntosh,
National Institutes of Health, Bethesda, MD, USA) and linear
measurements made of skull length, nasal height and length,
mandibular height and length as previously described (45), with
the length and misalignment of the upper and lower incisors
measured using the co-ordinates shown in Figure 7B and C. In
addition, external cranial volume was calculated as the volume
of a spheroid, using the equation:
4=3p cranial length  cranial height  cranial width
using the co-ordinates shown in Figure 7A and B. Similarly, the
dome angle was calculated by drawing a line joining the inter-
section of the interparietal bones and the squamous portion of
the occipital bone with the ridge dorsal to the junction of the
maxilla with the frontal and lacrymal bones, then determining
the position of the perpendicular line giving the highest point to
the dorsal surface. Using these co-ordinates (Fig. 7B), dome an-
gle (q ; in degrees) was calculated as:
h ¼ arctan yz=xyð Þ  ð360=2pÞ
Femora
Trabecular microarchitecture was assessed in the distal femora
using a high-resolution m-CT system (Skyscan 1072, Kontich,
Belgium) as previously described in rats (35). Femora were
thawed immediately before scanning, mounted on the sample
presentation stage and orientated by taking a series of single
images. Scanning was conducted at 50 kV and 210 mA, using a
resolution of 5.57 mm, 8 s exposures, a magnification of 27.34, a
rotation step of 0.45 and a 1 mm aluminium filter. After scan-
ning, each femur was re-wrapped in saline-soaked gauze,
re-frozen and stored for subsequent strength testing. An area of
the secondary spongiosa of the distal femora (1 mm3 0.5 mm
below the centre of the epiphyseal plate) was analysed using
the CT analyzer (CT-An; http://www.skyscan.be/products/nre
con.htm). Trabecular bone was separated from cortical bone
within the area of interest by using the freehand drawing tool in
CT-An.
Vertebrae
Trabecular architecture in L5 vertebral bodies was assessed as
above, but due to their small size, vertebrae were stabilized with
cotton wool inside a 1.5 ml Eppendorf tube, the cotton wool be-
ing moistened with phosphate-buffered saline to prevent dehy-
dration. Scanning was conducted using the same parameters as
above and the vertebrae re-frozen prior to strength testing.
Before analysing the trabecular architecture, reconstructed 3D
images were rotated with DataViewer (http://www.skyscan.be/
products/dataviewer.htm) to achieve a consistent orientation.
A 1.002 mm transverse section 30 slices (0.176 mm) rostral to
the centre of the caudal growth plate was analysed using CT-
An. The region of interest was restricted to the trabecular bone
within the vertebral body. In addition, vertebral size was deter-
mined by measuring the distance from the centre of the epiphy-
seal plates and the thickness of the cortical bone at the most
dorsal point of the vertebral body measured.
Figure 7. Quantification of skull morphology in WT and Opa3L122P mice. Linear measurements were made of skull length (a–b); cranial length (a–c); cranial height (d–e);
cranial width (f–g); cranial dome angle (q; calculated from the xyz co-ordinates as described in the text); nasal height (h-i); nasal length (i–b), mandibular height (j–k);
mandibular length (l–m); upper incisor length (n–o); lower incisor length (p–q); incisor misalignment (r–s) on m-CT reconstructions showing dorsal (A) right ventral (B),
and frontal (C) aspects (scale bar¼ 2 mm).
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Strength testing
a. Three point bending in femora
Mechanical strength of the femoral cortex was quantified by
three-point bending as previously described (41), with the lower
rollers set at 6.42 and 4.04 mm apart for WT and Opa3L122P fem-
ora, respectively, and the central roller positioned equidistant
from the lower rollers over the thinnest part of the mid-
diaphyseal region, to give a roughly posterior load direction.
Each bone was loaded at a crosshead speed of 2 mm/min until
failure, with load and displacement data recorded by a Zwick
Z050 tensile testing machine fitted with a 1 kN load cell (Zwick
Testing Machines Ltd., Leominster, Herefordshire, UK). Ultimate
tensile stress was calculated using failure load, morphometric
measurements of cortical wall thicknesses and diameters
(quantified from the cross-sectional m-CT image corresponding
to the site of fracture as determined by measuring the distance
from the end of the femur to the fracture point using a hand-
held micrometer) and simple beam theory (41).
b. Compressive strength in vertebrae
We adapted the method of Moskilde et al. (56) to quantify the
mechanical strength of the L5 vertebrae. After removing any re-
maining soft tissue, the neural arch and transverse processes
were carefully removed from each vertebra, to leave only the
vertebral body. The caudal epiphyseal plate was carefully re-
moved and the sample mounted caudal end down in Araldite
on a small metal plate and left for 24 h to set. The rostral epiph-
yseal plate was then removed with a diamond saw, prior to the
collection of a 0.8 mm section of vertebral body consisting of the
trabecular core and cortical border, but without any growth
plate or other soft tissue. Compressive strength of these verte-
bral body slices was tested in a rostro-caudal direction using the
Zwick Z050 tensile testing machine. Load-deformation curves
were recorded continuously via the Zwick Test Expert software,
with maximum stress (rmax) calculated by dividing maximum
load (Fmax) by the cross sectional area of the vertebral body (as
determined by m-CT).
Quantification of marrow adiposity
Marrow adiposity was determined as previously described
(33,36,43). In brief, three 7 mm anterior-posterior tibial sec-
tions and three dorso-ventral vertebral body sections were
stained with Toluidene Blue. Digital photomicrographs were
analysed with National Institutes of Health (NIH) Image J, to
quantify %-adiposity, adipocyte number and the adipocyte
size profile.
Statistics
Results are expressed as mean6SEM, and compared by un-
paired Student’s t test (using GraphPad Prism, GraphPad
Software Inc., San Diego, CA., USA), with P< 0.05 considered sig-
nificantly different.
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